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OBJECTIVE—Liver-speciﬁc inactivation of carcinoembryonic
antigen-related cell adhesion molecule 1 (CEACAM1) by a dom-
inant-negative transgene (L-SACC1 mice) impaired insulin clear-
ance, caused insulin resistance, and increased hepatic lipogenesis.
To discern whether this phenotype reﬂects a physiological function
of CEACAM1 rather than the effect of the dominant-negative
transgene, we characterized the metabolic phenotype of mice with
null mutation of the Ceacam1 gene (Cc1
/).
RESEARCH DESIGN AND METHODS—Mice were originally
generated on a mixed C57BL/6x129sv genetic background and
then backcrossed 12 times onto the C57BL/6 background. More
than 70 male mice of each of the Cc1
/ and wild-type Cc1
/
groups were subjected to metabolic analyses, including insulin
tolerance, hyperinsulinemic-euglycemic clamp studies, insulin
secretion in response to glucose, and determination of fasting
serum insulin, C-peptide, triglyceride, and free fatty acid levels.
RESULTS—Like L-SACC1, Cc1
/ mice exhibited impairment of
insulin clearance and hyperinsulinemia, which caused insulin
resistance beginning at 2 months of age, when the mutation was
maintained on a mixed C57BL/6x129sv background, but not until
5–6 months of age on a homogeneous inbred C57BL/6 genetic
background. Hyperinsulinemic-euglycemic clamp studies re-
vealed that the inbred Cc1
/ mice developed insulin resistance
primarily in liver. Despite substantial expression of CEACAM1 in
pancreatic -cells, insulin secretion in response to glucose in
vivo and in isolated islets was normal in Cc1
/ mice (inbred and
outbred strains).
CONCLUSIONS—Intact insulin secretion in response to glu-
cose and impairment of insulin clearance in L-SACC1 and Cc1
/
mice suggest that the principal role of CEACAM1 in insulin
action is to mediate insulin clearance in liver. Diabetes 57:
2296–2303, 2008
I
n response to physiological stimuli, insulin is se-
creted from pancreatic -cells into the portal circu-
lation in a pulsatile manner. Through its ﬁrst
passage, 50% of the secreted insulin is cleared in
liver. Insulin clearance is a critical regulator of insulin
action. Impaired insulin clearance is seen in response to
peripheral insulin resistance. On the other hand, impaired
insulin clearance can be the primary cause of insulin
resistance by causing downregulation of insulin receptors
and hepatic lipogenesis, both of which result in insulin
resistance (1–3).
Insulin clearance in liver is mediated by receptor-medi-
ated insulin endocytosis followed by degradation (1,4).
Upon its phosphorylation by the insulin receptor, the
carcinoembryonic antigen-related cell adhesion molecule
1 (CEACAM1) takes part of the insulin-receptor endocy-
tosis complex to promote insulin uptake and removal in
the hepatocyte (5–7). Moreover, liver-speciﬁc overexpres-
sion of a dominant-negative S503A phosphorylation-
defective isoform of CEACAM1 impairs insulin clearance
and causes chronic hyperinsulinemia and insulin resis-
tance, together with increased visceral obesity and dyslip-
idemia in L-SACC1 mice (8–10). In agreement with this
ﬁnding, activation of SHP-1, a CEACAM1 phosphatase,
adversely affects glucose homeostasis by impairing insulin
clearance (9). These data suggest that CEACAM1 regulates
insulin action by promoting hepatic insulin clearance.
To further investigate its function in insulin action in
vivo, we have characterized the metabolic phenotype of
the Cc1
/ mice homozygous for null mutation of the
Ceacam1 gene. We report here that, similar to liver-
speciﬁc inactivation of CEACAM1, its null mutation causes
impaired insulin clearance, hyperinsulinemia, hepatic ste-
atosis, and visceral adiposity. Moreover, the phenotype is
associated with hepatic insulin resistance, which is evi-
dent at an earlier age, when the mutation is propagated on
a mixed C57BL/6x129sv compared with a homogenous
C57BL/6 genetic background. These data suggest that the
principal role of CEACAM1 is to promote insulin clearance
in liver.
RESEARCH DESIGN AND METHODS
Animal husbandry. Cc1
/-null mice were generated on a mixed C57BL/
6x129sv background and backcrossed 12 times onto the C57BL/6 background
(11). Animals were kept in a 12-h dark/light cycle and fed standard chow ad
libitum. All procedures were approved by the Institutional Animal Care and
Utilization Committee. Male mice from 2 to 10 months of age were studied.
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2296 DIABETES, VOL. 57, SEPTEMBER 2008Metabolic analysis. After an overnight fast (from 1700 until 1100 h the next
day), mice were anesthetized with sodium pentobarbital (55 mg/kg body wt),
and whole venous blood was drawn from retroorbital sinuses to measure
fasting glucose levels using a glucometer (Accu-chek Aviva; Roche), serum
insulin and C-peptide levels by radioimmunoassays (Linco), serum FFAs by
NEFA C kit (Wako), and serum triglycerides (Pointe Scientiﬁc). Serum total
bilirubin and cholesterol were measured using a bilirubin calibrator and
Inﬁnity Cholesterol reagent (Sigma), respectively, and blood uric acid was
measured using Inﬁnity BUN reagent (Sigma). Visceral adiposity was ex-
pressed as percentage weight of white adipose tissue per total body weight.
Hyperinsulinemic-euglycemic clamps to assess insulin action in vivo.
After an overnight fast, a 2-h hyperinsulinemic-euglycemic clamp was con-
ducted in awake mice (n  1112) with a primed (150 mU/kg body wt) and
continuous infusion of human regular insulin (Humulin) at a rate of 2.5 mU 
kg
1  min
1 to raise serum insulin within a physiological range (10). Basal and
insulin-stimulated whole-body glucose turnover were estimated with a con-
tinuous infusion of [3-
3H]glucose (PerkinElmer Life and Analytical Sciences)
for 2 h before (0.05 Ci/min) and throughout the clamps (0.1 Ci/min). Tissues
were removed to determine glycogen (10) and triglyceride (12) content.
Insulin tolerance test. After an overnight fast (1700 until 1100 h the next
day), mice were anesthetized and injected intraperitoneally with 0.125 units
insulin/kg body wt, and their venous blood from the retroorbital sinuses was
drawn at 0–5 h after injection to determine blood glucose levels.
Intraperitoneal glucose tolerance test and acute insulin secretion.
After an overnight fast (1700 until 0800 h the next day), anesthetized mice
were injected intraperitoneally with glucose (2.0 g/kg body wt), and their
venous blood was drawn at 0–30 min after injection to determine blood
glucose and serum insulin levels.
Glucose-6-phosphate content. Liver was removed from randomly fed mice
and snap-frozen, and glucose-6-phosphate (G6P) content was determined in
1-g tissue homogenates using G6P dehydrogenase (12). Absorbance was
measured at 340 nm before and after addition of enzyme.
Cell culture. Murine -TC6 cells (13) and Min-6 -cells (14) were maintained
at 37°C and 5% CO2 in Dulbecco’s modiﬁed Eagle’s medium containing 10%
fetal bovine serum and penicillin and streptomycin. All experiments were
performed on 80% conﬂuent cells.
Western blot. The concentration of proteins in tissue and serum lysates was
quantitated by BCA protein assay (Pierce) before analysis by 7 or 4–12%
gradient SDS-PAGE (Invitrogen), respectively, and immunoprobing with spe-
ciﬁc antibodies. These included polyclonal antibodies against ApoB48/100
(Chemicon International), fatty acid synthase (FAS) (15), and fatty acid
transporter-1 (FATP-1) (I-20; Santa Cruz Biotechnology) in addition to mono-
clonal antibodies against actin (Sigma) and tubulin (Sigma). Blots were
incubated with horseradish peroxidase–conjugated anti-goat IgG (Santa Cruz
Biotechnology), anti-mouse IgG (Amersham), and anti-rabbit IgG (Amersham)
antibodies, and proteins were detected by enhanced chemiluminescence
(Amersham) and quantiﬁed by densitometry.
Pancreatic cells were lysed, and 1 mg protein was subjected to immuno-
precipitation, as previously described with an anti-mouse polyclonal antibody
against BGP1 (-mCC1; Ab-231) (16) and analysis on SDS-PAGE, followed by
immunoprobing with Ab-231 to normalize for the amount of CEACAM1 in the
immunopellet.
For phosphorylation experiments, livers were removed, and 200 g lysates
was treated with 100 nmol/l insulin for 5 min before immunoprecipitation
with antibodies against the -subunit of the insulin receptor (-IR) (Santa
Cruz Biotechnology) followed by SDS-PAGE analysis and immunoblotting
with -phosphotyrosine antibody (-pTyr) (Upstate Biotechnology), followed
by -IR to normalize against the amount of insulin receptor in the immu-
nopellet.
Northern blot. Liver mRNA was puriﬁed using TRIzol (Invitrogen) followed
by the MicroPoly (A) Pure kit (Ambion) and analysis by probing with cDNAs
for glucose-6-phosphatase (G6Pase), carnitine palmitoyl transferase 1 (CPT1),
PEPCK, pyruvate dehydrogenate kinase (PDK-4), glucokinase, and sterol
regulatory element–binding protein 1c (SREBP-1c), using the Random Primed
DNA Labeling kit (Roche) before reprobing with -actin cDNA to normalize
against the amount of mRNA applied.
Insulin secretion from isolated islets. Islets were puriﬁed from pancreata
of 6-month-old mice by collagenase digestion (17). Islets were resuspended in
RPMI containing 10% newborn calf serum and 5.5 mmol/l glucose and cultured
overnight at 37°C. Islets were stimulated with glucose (2.8–16.8 mmol/l) or 20
mmol/l KCl for1ha t37°C and collected by centrifugation, and the superna-
tant was assayed for insulin content by radioimmunoassay. Islets were
dissolved in high-salt buffer and sonicated three times at 80 watts for 10 s, and
DNA concentration was determined to normalize insulin content.
Fluorescence-activated cell sorter puriﬁcation of isolated islets. Islets
were isolated by the intraductal collagenase digestion method (18). After PBS
wash, the suspension was passed through a 35-m ﬁlter before ﬂuorescence-
activated cell sorter (FACS) analysis, based on autoﬂuorescence and size (19).
Cells were sorted directly into TRIzol reagent, and the purity of the sorted
fractions was determined by real-time PCR for insulin and glucagon in each
fraction.
-Cell area and immunohistochemistry. Mice were anesthetized, and
pancreata were dissected, weighed, ﬁxed in Bouin’s solution, sectioned, and
stained (20). Antibodies used for the immunoﬂuorescence staining were:
guinea pig anti-human insulin (Linco Research) and AMCA-conjugated donkey
anti–guinea pig antibody (Jackson Immunoresearch) for insulin; anti-mouse
glucagons monoclonal antibody (Sigma) and Texas red–conjugated donkey
anti-mouse antibody (Jackson Immunoresearch) for glucagon; and anti-
somatostatin rabbit polyclonal antibody (Abcam) and Cy2-conjugated donkey
anti-rabbit antibody (Jackson Immunoresearch) for somatostatin. -Cell area
was calculated by morphometric analysis using Image J software (National
Institutes of Health; http://rsb.info.nih.gov/ij/), and the insulin-stained area
was divided by total pancreas area.
Real-time PCR. RNA was extracted using TRIzol method according to the
manufacturer’s protocol. After DNAse digestion (DNAfree; Ambion), 100 ng
RNA was transcribed into cDNA in a 20-l reaction using a High Capacity
cDNA Archive kit (Applied Biosystems), analyzed, and ampliﬁed (ABI 7900 HT
system). PCR was performed in a 10-l reaction, containing 5 l cDNA
(one-ﬁfth diluted), 1SYBR Green PCR Master Mix (Applied Biosystems), and
300 nmol/l of each primer: Ceacam1 forward primer, AATCTGCCCCTGG
CGCTTGGAGCC; Ceacam1 reverse primer, AAATCGCACAGTCGCCTGAG
TACG; -actin forward primer, AGGGCTATGCTCTCCCTCAC; and -actin
reverse primer, AAGGAAGGCTGGAAAAGAGC.
TABLE 1
Metabolic parameters of inbred C57BL/6 mice
2 months 6 months
Cc1
/ Cc1
/ Cc1
/ Cc1
/
Body wt (g) 21. 	 0.2 22. 	 0.3* 27. 	 0.3 31. 	 0.3*
Visceral fat/body wt (%) 0.9 	 0.1 1.2 	 0.1* 1.9 	 0.1* 3.3 	 0.3*
Lean mass/body wt (%) 85. 	 0.7 84. 	 0.7 78. 	 0.9 73. 	 1.2*
Total fat/body wt (%) 15. 	 0.7 16. 	 0.7 22. 	 0.9 27. 	 1.2*
Serum insulin (ng/ml) 0.6 	 0.0 0.8 	 0.1* 0.4 	 0.0 0.8 	 0.1*
Serum C-peptide (ng/ml) 1.7 	 0.3 2.4 	 0.2* 0.6 	 0.1 1.2 	 0.3*
Steady-state C/I 5.0 	 0.5 3.9 	 0.2* 3.1 	 0.2 2.4 	 0.2*
Serum FFA (mEq/l) 0.5 	 0.0 0.5 	 0.0 0.7 	 0.1 1.0 	 0.1*
Serum triglyceride (mg/dl) 51. 	 3.2 62. 	 2.5* 61. 	 5.0 54. 	 2.4
Fasting glucose (mg/dl) 123. 	 2.0 112. 	 1.9* 102. 	 1.8 96 	 2.1*
Random glucose (mg/dl) 137. 	 14.0 119. 	 2.11 119. 	 2.12 100. 	 3.29*
Hepatic triglyceride (g/mg protein) 89.0 	 7.10 133. 	 13.6* 62.7 	 8.3 97.7 	 9.43*
Muscle triglyceride (g/mg protein) 11.4 	 1.90 8.20 	 2.10 4.36 	 0.75 6.39 	 1.62
Data are means 	 SE. *P 
 0.05 Cc1
/ vs. Cc1
/ control mice.
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PCR product relative to -actin. The relative amount of mRNA was calculated
as 2CT. Results are expressed in fold change as means 	 SE.
Statistical analysis. Data were analyzed with SPSS software using one-
factor ANOVA analysis or Student’s t test. P 
 0.05 was statistically signiﬁcant.
RESULTS
Body weight and composition in inbred Cc1
/ mice.
Cc1
/ mice on inbred C57BL/6 genetic background ex-
hibit an increase in body weight in comparison with their
wild-type (Cc1
/) counterparts, starting at 2 months of
age (Table 1). Parallel increase in whole-body fat mass, as
assessed by
1H-magnetic resonance spectrometry (Table
1), is attributed to increased visceral adiposity, as mea-
sured by % visceral fat per body weight, but not to lean
mass (Table 1).
Hyperinsulinemia and impaired insulin clearance in
inbred Cc1
/ mice. Null mutation of Ceacam1 does not
alter liver function, as indicated by normal serum choles-
terol (77.5 	 5.30 in Cc1
/ vs. 86.0 	 3.74 mg/dl in Cc1
/
mice; P  0.05) and total bilirubin levels (0.29 	 0.02 in
Cc1
/ vs. 0.27 	 0.02 mg/dl in Cc1
/ mice; P  0.05).
Similarly, kidney function, as assessed by normal serum
uric acid level (1.38 	 0.15 vs. 1.24 	 0.11 mg/dl in Cc1
/
mice; P  0.05), is intact in Cc1
/ mice.
Inbred Cc1
/ mice exhibit a slight increase (1.5- to
2.0-fold) in fasting serum insulin levels, starting at 2
months of age (Table 1). Insulin clearance, measured by
steady-state C-peptide–to–insulin molar ratio, is signiﬁ-
cantly reduced (by 1.5-fold) in 2- to 6-month-old Cc1
/
relative to Cc1
/ mice (Table 1). Furthermore, insulin
injection in 2- and 6-month-old Cc1
/ mice results in a
prolonged suppression of blood glucose, as opposed to
Cc1
/, in which glucose levels return to basal in 3–4 h
(Fig. 1). This suggests that Cc1
/ mice clear exogenous
insulin less efﬁciently. Taken together, the data propose
that null mutation of Ceacam1 causes hyperinsulinemia
and impairs insulin clearance.
Secondary insulin resistance in older inbred Cc1
/
mice. The steady-state glucose infusion rate required to
maintain euglycemia during the clamp is normal in
3-month-old Cc1
/ mice (47.2 	 1.8 vs. 48.0 	 1.5 mg 
kg
1  min
1 in Cc1
/ mice; P  0.05), suggesting intact
insulin action at this age. Consistently, the suppressive
effect of insulin on hepatic glucose production (HGP) is
intact (97.3 	 1.7 vs. 97.4 	 1.3% in Cc1
/ mice; P  0.05),
and insulin-stimulated glucose uptake in white adipose
tissue is elevated by twofold in these mice (28.0 	 4.0 vs.
14.0 	 3.0 nmol  g
1  min
1 in Cc1
/ mice; P 
 0.05).
In contrast, 6-month-old Cc1
/ mice exhibit reduction
in steady-state glucose infusion rate (Fig. 2A), suggesting
insulin resistance (Table 2). At this age, Cc1
/ mice
exhibit a marked hepatic insulin resistance, as reﬂected by
an 14-fold increase in HGP during clamps (Fig. 2D) and
reduced ability to suppress HGP (23.4 	 10.2 vs. 79.6 	
12.6% in Cc1
/ mice; P 
 0.005) (Fig. 2E).
Insulin suppresses HGP by inhibiting gluconeogenesis
and stimulating net hepatic glucose uptake and subse-
quent glycogen synthesis (21). Increase in fasting Pepck
mRNA levels (Fig. 3A, i) suggests increased gluconeogen-
esis, and elevation in postprandial Pdk4 with normal,
rather than reduced, Pepck mRNA levels (Fig. 3A, ii)
suggests that the suppressive effect of insulin on glucone-
ogenesis is reduced in older Cc1
/ mice. Together with
increased fatty acid oxidation at the fed state, as suggested
by higher Cpt1 mRNA levels, and given that FFAs play a
signiﬁcant role in hepatic autoregulation of glucose pro-
duction (22), the data suggest that the liver of Cc1
/ mice
is geared toward gluconeogenesis, as manifested by higher
levels of fed G6P content (0.31 	 0.03 vs. 0.17 	 0.05
mol/g wet tissue in Cc1
/ mice; P 
 0.05) (Fig. 3B)
rather than glucose, due to reduced G6Pase mRNA levels
(Fig. 3A, ii). This could in part underlie the lower basal
HGP in the Cc1
/ mouse (84.6 	 4.2 vs. 119.3 	 12.1 nmol 
g
1  min
1 in Cc1
/ mice; P 
 0.05).
Whole-body glycogen synthesis is decreased in adult
Cc1
/ mice (Fig. 2B). With glycogen synthesis in muscle
being normal (P  0.05) (Fig. 2G), this suggests that the
B
l
o
o
d
 
G
l
u
c
o
s
e
(
%
 
B
a
s
a
l
)
Post-Insulin (h)
2 Mos
012 3 45
110
50
60
70
80
90
100
*
*
Cc1–/–
Cc1+/+
6 Mos
*
0 1234
Cc1–/–
Cc1+/+
Post-Insulin (h)
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FIG. 2. Insulin response during hyperinsulinemic-euglycemic clamps in
awake inbred mice. Five- to 6-month-old wild-type Cc1
/ () and
Cc1
/ mice (f)( n > 10 per group) were subjected to clamp analysis.
A: Steady-state glucose infusion rates during euglycemic clamps. B:
Insulin-stimulated whole-body glycogen synthesis. C: Insulin-
stimulated whole-body glucose turnover. D: HGP during basal and
insulin-stimulated (clamp) states. E: Hepatic insulin action repre-
sented as insulin-mediated percent suppression of HGP. F: Insulin-
stimulated glucose uptake in skeletal muscle (gastrocnemius). G:
Skeletal muscle glycogen synthesis. H: Insulin-stimulated glucose up-
take in white adipose tissue (WAT). Values (all in nmol  g
1  min
1)
are expressed as means  SE. *P < 0.05 vs. Cc1
/.
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2298 DIABETES, VOL. 57, SEPTEMBER 2008decrease in glycogen synthesis is primarily hepatic. With
the mRNA level of fed hepatic glucokinase being intact
(Fig. 3A, ii), it is possible that the increase in G6P content
exerts a negative feedback effect on glucokinase activity to
limit glycogen synthesis in Cc1
/ mice because glycogen
energy store is not diminished (4.34 	 0.61 vs. 2.79 	 0.56
mg glycogen/g wet tissue in Cc1
/ mice; P  0.05).
Although this hypothesis needs to be tested, it supports the
notion that increase in G6P content mostly derives from
reduced suppressive effect of insulin on gluconeogenesis.
Insulin-stimulated whole-body glucose turnover is unal-
tered in Cc1
/ mice (P  0.05) (Fig. 2C). This is consis-
tent with normal glucose uptake (Fig. 2F) and glycolysis
(not shown) in skeletal muscle (P  0.05) and with an
insigniﬁcant decrease in glucose uptake in white adipose
tissue (P  0.05) (Fig. 2H). Preservation of peripheral
insulin sensitivity could compensate for elevation in glu-
coneogenesis and hepatic insulin resistance and contrib-
ute, with decreased G6Pase levels, to lower basal HGP in
Cc1
/ (Fig. 2D).
Altered lipid metabolism in older inbred Cc1
/ mice.
As expected from the positive transcriptional effect of
hyperinsulinemia on lipogenic enzymes (23), Srebp-1c
mRNA (Fig. 3A, ii) and FAS protein content (Fig. 4A) are
elevated in fed 6-month-old Cc1
/ mice. This suggests
increased de novo lipogenesis in Cc1
/ mice, as we have
previously shown (24). Moreover, fasting serum FFA lev-
els are signiﬁcantly elevated (1.5-fold) in parallel to
increased visceral adiposity in these mice (Table 1). This
suggests increased FFA mobilization out of the adipose
tissue and transport into liver, where FFAs are partitioned
into the triglyceride synthetic pathways to contribute to
increased triglyceride levels beginning at 2 months of age
(Table 1).
TABLE 2
Metabolic parameters at basal state (overnight fasted) and during a 2-h hyperinsulinemic-euglycemic clamp experiment in
6-month-old inbred mice
Basal period Ccl clamp period
n
Body
wt (g)
Plasma glucose
(mmol/l)
Plasma insulin
(g/ml)
Plasma glucose
(mmol/l)
Plasma insulin
(g/ml)
Cc1
/ 52 3 	 1 9.7 	 0.4 0.08 	 0.01 7.3 	 0.5 0.51 	 0.06
Cc1
/ 72 9 	 1* 8.5 	 0.5 0.14 	 0.02* 6.9 	 0.4 0.60 	 0.08
Data are means 	 SE. *P 
 0.05 vs. Cc1
/ mice by Student’s t test.
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FIG. 3. Northern blot analysis and quantitation of glucose intermedi-
ates in livers of inbred mice. Livers from 6-month-old wild-type Cc1
/
() and Cc1
/ mice (f)( n > 7 per group) were isolated for mRNA
analysis by Northern blot (A) and determination of hepatic G6P levels
(B). Representative Northern gels from analysis of mRNA levels at
fasting and fed states are shown normalized to -actin. Values ex-
pressed as means  SE. *P < 0.05 vs. Cc1
/.
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FIG. 4. Western blot analysis of proteins involved in lipid homeostasis
in inbred mice. Tissues (A, C, and D) were removed from 6-month-old
inbred Cc1
/ mice (n > 5 per group), and lysates were analyzed by 7%
SDS-PAGE and sequential immunoblotting with -FAS and -FATP-1
antibodies followed by reprobing with -tubulin or -actin antibodies
to account for the amount of proteins analyzed. B: Serum was diluted
and analyzed by 4–10% gradient SDS-PAGE and immunoblotting with
an antibody against apolipoprotein (apo)B, which recognizes both
apoB48 and apoB100. A representative gel of ﬁve to six mice per group
is included.
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output, as assessed by elevation in serum ApoB48/
ApoB100 protein levels (Fig. 4B). With steady-state serum
triglyceride levels being normal (Table 1), it is likely that
triglyceride is redistributed to the white adipose tissue, as
suggested by elevation in FATP-1 and FAS protein content
(Fig. 4C), rather than to skeletal muscle, in which FATP-1
protein levels are reduced (Fig. 4D) and triglyceride con-
tent is unaltered (Table 1).
Normal pancreatic -cell function and area in inbred
Cc1
/ mice. Western blot analysis reveals that
CEACAM1 is highly expressed in FACS-puriﬁed mouse
pancreatic -cells (Fig. 5A, i). Consistently, CEACAM1 is
expressed in murine -Min6 but not in -TC6 cells (Fig. 5A,
i). Quantitative RT-PCR analysis reveals that Ceacam1
mRNA is expressed at a ratio of 2:1 in FACS-puriﬁed
mouse pancreatic -cells relative to non–-cells (Fig. 5A,
ii). Acute-phase insulin secretion in response to glucose
remains intact even at 10 months of age, with the area
under the curve being comparable with that in Cc1
/
mice (P  0.05) (Fig. 5B), at which point, both insulin
(0.53 	 0.06 vs. 0.26 	 0.01 ng/ml in Cc1
/ mice; P 
 0.05)
and C-peptide levels (2.73 	 0.74 vs. 0.39 	 0.06 ng/ml in
Cc1
/ mice; P 
 0.05) are elevated. Moreover, -cell area
is intact in 6-month-old Cc1
/ mice, as assessed by
immunohistochemical analysis with -insulin antibody
(blue) (Fig. 5C). Similarly, immunostaining with -gluca-
gon (red) reveals normal -cell area relative to Cc1
/
mice. Taken together, the data suggest that Ceacam1
deletion does not adversely affect -cell area or secretory
function.
Earlier onset of insulin resistance in outbred Cc1
/
mice. Similar to inbred mice, outbred Cc1
/ mice on
mixed C57BL/6x129sv background exhibit an increase in
body weight and visceral obesity compared with their
wild-type counterparts at all ages examined (Table 3).
Outbred Cc1
/ mice exhibit hyperinsulinemia (3- to
4.3-fold) and a 1.5-fold decrease in insulin clearance
beginning at 2 months of age (Table 3). Consistently,
glucose level remains suppressed for 3 h after insulin
injection in these mice as opposed to Cc1
/ mice, in
which glucose levels return to basal within 2 h (Fig. 6A).
Impaired insulin clearance yields insulin resistance start-
ing at 2 months of age, as indicated by random hypergly-
cemia (Table 3) and glucose intolerance (Fig. 6B; with
blood glucose of 387 	 92 vs. 185 	 18 mg/dl in Cc1
/
mice at 2 h after glucose injection; P 
 0.0001). Be-
cause glucose levels decrease to a similar extent in 2- (Fig.
6A) and 6-month-old outbred Cc1
/ and Cc1
/ mice
after insulin injection (not shown), insulin response in
peripheral tissues appears to be normal. Western blot
analysis of immunopellets of the insulin receptor -sub-
unit (IR) using phosphotyrosine antibody (-pTyr), re-
veals decreased ability of insulin to induce IR
phosphorylation in liver lysates of 2-month-old Cc1
/
compared with Cc1
/ mice (Fig. 6C). Outbred Cc1
/
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FIG. 5. The effect of Ceacam1 on insulin secretion and -cell area. A: i,
CEACAM1 protein content in immortalized -cell islets from IRKO
mice and in -TC6 and -Min6 cells was analyzed by Western blot
analysis using an antibody against mouse CEACAM1. ii, Ceacam1
mRNA levels were determined in FACS-puriﬁed -cells and non–-cells
derived from a normal mouse by real-time PCR analysis. Data are
normalized for -actin and expressed as fold change. B: Insulin levels
in response to glucose were measured for 0–30 min after intraperito-
neal injection of age-matched 6- and 10-month-old inbred Cc1
/ (E)
and Cc1
/ mice (F). Experiments were performed on n > 7 per group.
Values are expressed as means  SE. *P < 0.05 vs. Cc1
/. C: Pancreas
sections from four each of the 6-month-old inbred Cc1
/ and Cc1
/
mice were ﬁxed and immunostained with antibodies against insulin
(blue), glucagon (red), and somatostatin (green). -Cell area was
estimated by morphometric analysis of 44 islets from Cc1
/ and 33
from Cc1
/ mice. Values expressed as means  SE in arbitrary units
(AU) are presented in the graph. Magniﬁcation 20. (Please see
http://dx.doi.org/10.2337/db08-0379 for a high-quality digital represen-
tation of this ﬁgure.)
TABLE 3
Metabolic parameters of outbred B6x129sv mice
2 months 6 months
Cc1
/ Cc1
/ Cc1
/ Cc1
/
Body wt (g) 23.7 	 0.85 26.9 	 0.92* 31.0 	 1.10 35.2 	 0.84*
% Visceral fat/body wt 1.22 	 0.10 2.00 	 0.13* 1.81 	 0.27 3.37 	 0.35*
Serum insulin (ng/ml) 0.51 	 0.09 1.57 	 0.29* 0.25 	 0.03 1.04 	 0.26*
Serum C-peptide (ng/ml) 2.69 	 0.36 5.34 	 0.93* 2.04 	 0.14 3.28 	 0.56*
Steady-state C/I 5.89 	 0.85 3.50 	 0.66* 4.42 	 0.28 3.39 	 0.31*
Serum FFA (mEq/l) 0.40 	 0.02 0.75 	 0.09* 0.50 	 0.04 1.12 	 0.15*
Serum triglyceride (mg/dl) 53.3 	 5.20 78.2 	 7.80* 59.6 	 5.25 84.9 	 8.41*
Fasting glucose (mg/dl) 96.2 	 3.62 96.5 	 3.40 81.3 	 1.10 87.9 	 6.64
Random glucose (mg/dl) 134. 	 5.22 151. 	 5.40* 133. 	 9.90 157. 	 9.54*
Data are means 	 SE. *P 
 0.05 Cc1
/ vs. Cc1
/ control mice.
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triglyceride levels starting at 2 months of age (Table 3).
Taken together, the data suggest that outbred Cc1
/ mice
develop altered lipid metabolism and insulin resistance,
primarily in liver, with a more rapid onset than the inbred
mice.
Serum C-peptide levels are mildly elevated (by 1.5-
fold) in outbred Cc1
/ mice (Table 3), suggesting com-
pensatory increase in insulin secretion. Acute-phase
insulin secretion in response to glucose is intact (not
shown), and insulin secretion in response to increasing
glucose levels and 20 mmol/l KCl is normal in primary
islets derived from 6-month-old outbred Cc1
/ mice (Fig.
6D). Fasting serum glucagon level is also normal in these
mice (40.19 	 0.89 vs. 42.36 	 1.99 pg/ml in Cc1
/ mice;
P  0.05). This suggests that Ceacam1 deletion does not
affect insulin secretion when propagated on the mixed
C57BL/6x129sv background.
DISCUSSION
L-SACC1 transgenic mice with liver inactivation of
CEACAM1 demonstrated that CEACAM1 promotes insulin
action by coordinated regulation of insulin and lipid
metabolism (8,10,24). The purpose of this study was to use
the null Cc1
/ mouse to reevaluate the role of CEACAM1
in insulin action in the absence of the potential confound-
ing effect of the dominant-negative transgene. We herein
report that homozygosity for a null Cc1 allele phenocopies
transgenic inactivation of CEACAM1 in liver and causes
visceral obesity together with impairment of insulin clear-
ance and hyperinsulinemia, followed by insulin resistance,
with an earlier onset when propagated on a mixed C57BL/
6x129sv relative to pure C57BL/6 background (as with null
mutation of the insulin receptor substrate 2 gene [25,26]).
Despite abundant expression in -cells, null mutation of
Ceacam1 does not reduce -cell secretory function or
-cell area in response to glucose. This supports a key role
for CEACAM1 in promoting hepatic insulin clearance.
Like its liver-speciﬁc inactivation, null mutation of
Ceacam1 impairs insulin clearance and causes hyperinsu-
linemia and hepatic insulin resistance in association with
increased steatosis. These ﬁndings are consistent with the
high expression of CEACAM1 in liver (27), a major site
for insulin clearance. We have shown that CEACAM1-
dependent pathways mediate a decrease in FAS activity to
protect the liver from the lipogenic effect of high insulin
levels in portal vein and that this effect is abolished in the
hyperinsulinemic Ceacam1 mutant mice (24). Together
with increased Srebp-1c mRNA and FAS protein levels,
this leads to increased de novo lipogenesis and contributes
to increase in hepatic triglyceride content in Cc1
/ mice.
Moreover, these mice exhibit a reduction in the suppres-
sive effect of insulin on lipid oxidation and gluconeogen-
esis, which is manifested by increased G6P content,
which, in association with reduced G6Pase mRNA level
(and presumably activity), is partitioned to the triglyceride
synthetic pathways. The data suggest that null mutation of
Ceacam1 chronically gears the liver toward steatosis by
increasing hepatic FFA supply and de novo lipogenesis in
addition to increasing G6P production and its partitioning
toward triglyceride synthesis.
Consistent with a positive correlation between liver
steatosis, hyperinsulinemia, and high serum ApoB levels in
humans and rodents (23,28–31), serum ApoB100/48 levels
are elevated in Cc1
/ mice, suggesting increased triglyc-
eride output. Normal circulating triglyceride levels sup-
port redistribution into peripheral tissues in response to
compensatory increase in insulin secretion. As in leptin
deﬁciency (32) and transgenic lipoatrophic AZIP mutation
(33), propagation of Ceacam1 deletion on the C57BL/6
genetic background favors substrate redistribution to the
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FIG. 6. Insulin resistance in outbred C57BL/6x129sv mice. A: For
insulin tolerance, glucose levels were measured in venous blood ex-
tracted from overnight-fasted 6-month-old age-matched wild-type
Cc1
/ (E) and Cc1
/ mice (F) injected intraperitoneally with 0.125
units/kg insulin for 0–3 h. Experiments were performed on n > 9 per
group. Values are expressed as means  SE. *P < 0.05 vs. Cc1
/. B: For
glucose tolerance test, blood glucose level was determined in over-
night-fasted 2-month-old Cc1
/ (E) and Cc1
/ mice (F) mice at 0–120
min after intraperitoneal glucose injection (2 g/kg). Six to 11 mice
were used in each group. Values are expressed as means  SE. *P <
0.05 vs. Cc1
/. C: For Western blot analysis of insulin receptor
phosphorylation, liver lysates of 2-month-old outbred Cc1
/ and
Cc1
/ controls were incubated with () or without () 100 nmol/l
insulin. The IR was immunoprecipitated (Ip), analyzed by 7% SDS-
PAGE, and transferred to nitrocellulose membrane for immunoblotting
(Ib) with horseradish peroxidase–conjugated phosphotyrosine (-
pTyr) antibody (i). Membranes were reprobed (reIb) with -IR
antibody to account for the amount of insulin receptor in the immu-
nopellets (ii). The gel is representative of three different experiments
each performed on two mice per treatment per group. D: Islets were
isolated from 6-month-old wild-type Cc1
/ () and Cc1
/ mice (f)
(n > 3 per group) by collagenase digestion followed by centrifugation
over histopaque gradient. Recovered islets were cultured overnight in
RPMI containing 5.5 nmol/l glucose. Insulin secretion was assayed by
incubating 10 islets in Kreb’s buffer containing different concentra-
tions of glucose or 20 mmol/l KCl for 1 h. Amount of insulin secreted
was normalized with DNA content, and values are expressed as
means  SE.
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visceral obesity in Cc1
/ mice, it does not adversely
affect insulin action in the periphery, in particular in
muscle, where fatty acid uptake is reduced and triglycer-
ide content is normal. Selective increase in triglyceride
accumulation and alteration of insulin action in liver as
opposed to muscle appears to be common in the C57BL/6
strain, as has been suggested by the phenotype of Ob/Ob
(32) and lipoatrophic AZIP mice (33), which when propa-
gated onto the FVB background exhibit triglyceride parti-
tioning from liver to muscle. Likewise, transgenic
inactivation of CEACAM1 in liver causes insulin resistance
and fat accumulation in muscle and adipose tissue, in
addition to liver, when propagated on a C57BL/6xFVB
mixed background (8). In light of the modulation of the
diabetes phenotype by strain-related genetic factors (34),
it is possible that Ceacam1-null mutation would cause
insulin resistance in muscle if propagated on the FVB
genetic background. Conditional null mutation of the
insulin receptor in liver yields hepatic insulin resistance
with elevated lipogenesis and serum ApoB100/48 but with
reduced serum triglycerides in comparison with wild-type
mice (35). Whereas this mouse emphasizes the impact of
interrupted insulin signaling at the receptor level on
steatosis in liver, the Cc1
/ mouse phenotype highlights
the critical role of CEACAM1 in regulating insulin action
by coordinating insulin and lipid metabolism in liver and
subsequently in extrahepatic tissues. This in vivo demon-
stration of a distinct CEACAM1-dependent postreceptor
signaling pathway modulating insulin action by promoting
insulin clearance provides proof of principle that hyperin-
sulinemia and hepatic steatosis can be a primary cause of
insulin resistance, rather than a marker thereof.
Null mutation of Ceacam1 alters neither the insulin
secretory function of -cells in response to glucose nor
-cell area. Because -cell–speciﬁc null mutation of insu-
lin receptor (IRKO) causes reduction in acute-phase
insulin secretion in response to glucose (18), our ﬁnding
suggests that CEACAM1 does not modulate the insulin
signaling pathways mediating insulin secretion. It remains
possible that deletion of Ceacam1 is compensated for by
Ceacam2, a close relative of Ceacam1 (36), whose expres-
sion, albeit lower than that of Ceacam1 in -cells, is not
signiﬁcantly altered in the Cc1
/ mouse (not shown).
Taken together, the data suggest that the primary met-
abolic effect of Cc1 deﬁciency is impaired insulin clear-
ance rather than increased insulin secretion. The
underlying mechanism of insulin resistance induced by
hyperinsulinemia is a manifestation of several metabolic
and cellular abnormalities, including increased lipogenesis
in liver. This paradigm assigns a primary role for
CEACAM1 in regulating insulin action by promoting insu-
lin clearance and regulating lipogenesis in liver.
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